A detailed history of Elevatus Welath Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Elevatus Welath Management holds 4,923 shares of LLY stock, worth $3.78 Million. This represents 1.43% of its overall portfolio holdings.

Number of Shares
4,923
Previous 6,048 18.6%
Holding current value
$3.78 Million
Previous $5.48 Billion 20.35%
% of portfolio
1.43%
Previous 2.05%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$772.14 - $960.02 $868,657 - $1.08 Million
-1,125 Reduced 18.6%
4,923 $4.36 Billion
Q2 2024

Aug 14, 2024

SELL
$724.87 - $909.04 $3.56 Million - $4.46 Million
-4,907 Reduced 44.79%
6,048 $5.48 Billion
Q1 2024

May 10, 2024

BUY
$592.2 - $792.28 $6.05 Million - $8.09 Million
10,210 Added 1370.47%
10,955 $8.52 Billion
Q4 2023

Feb 12, 2024

BUY
$525.19 - $619.13 $28,360 - $33,433
54 Added 7.81%
745 $434 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $300,377 - $414,116
691 New
691 $371 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Elevatus Welath Management Portfolio

Follow Elevatus Welath Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Elevatus Welath Management, based on Form 13F filings with the SEC.

News

Stay updated on Elevatus Welath Management with notifications on news.